Why we aren’t studying it
24:56–25:30 · 34s
A blunt assessment: no profits, no studies. Casperson argues women’s neuroprotection is undervalued, blocking the big trials needed on generic testosterone.
24:56–25:30 · 34s
A blunt assessment: no profits, no studies. Casperson argues women’s neuroprotection is undervalued, blocking the big trials needed on generic testosterone.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.